OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A framework for fibrolamellar carcinoma research and clinical trials
Timothy A. Dinh, Alan F. Utria, Kevin C. Barry, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 5, pp. 328-342
Open Access | Times Cited: 41
Timothy A. Dinh, Alan F. Utria, Kevin C. Barry, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 5, pp. 328-342
Open Access | Times Cited: 41
Showing 1-25 of 41 citing articles:
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 4
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 4
PET‐Based Dual‐Modal Probes for In Vivo Imaging
Ruilong Zhao, Deren Lan, Bing Xia, et al.
Small (2025)
Open Access | Times Cited: 2
Ruilong Zhao, Deren Lan, Bing Xia, et al.
Small (2025)
Open Access | Times Cited: 2
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
Jens Bauer, Natalie Köhler, Yacine Maringer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
Jens Bauer, Natalie Köhler, Yacine Maringer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms
Gary K.L. Chan, Samantha Maisel, Yeonjoo Hwang, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 25
Gary K.L. Chan, Samantha Maisel, Yeonjoo Hwang, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 25
Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss
Laura Rüland, Francesco Andreatta, Simone Massalini, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 24
Laura Rüland, Francesco Andreatta, Simone Massalini, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 24
Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma
Sophia M. Lauer, Mitchell H. Omar, Martin Golkowski, et al.
Cell Reports (2024) Vol. 43, Iss. 2, pp. 113678-113678
Open Access | Times Cited: 6
Sophia M. Lauer, Mitchell H. Omar, Martin Golkowski, et al.
Cell Reports (2024) Vol. 43, Iss. 2, pp. 113678-113678
Open Access | Times Cited: 6
The therapeutically actionable long non-coding RNA ‘T-RECS’ is essential to cancer cells’ survival in NRAS/MAPK-driven melanoma
Valentin Feichtenschlager, Li-Nan Chen, Yixuan James Zheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Valentin Feichtenschlager, Li-Nan Chen, Yixuan James Zheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Protein kinase A and local signaling in cancer
Kacey Rosenthal, John D. Gordan, John D. Scott
Biochemical Journal (2024) Vol. 481, Iss. 22, pp. 1659-1677
Closed Access | Times Cited: 5
Kacey Rosenthal, John D. Gordan, John D. Scott
Biochemical Journal (2024) Vol. 481, Iss. 22, pp. 1659-1677
Closed Access | Times Cited: 5
The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway
Graeme B. Bolger
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 22
Graeme B. Bolger
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 22
S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 01, pp. e67-e161
Open Access | Times Cited: 4
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 01, pp. e67-e161
Open Access | Times Cited: 4
Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver
Jyotsna Gummadi, Xin Wei Wang, Changqing Xie
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 745-752
Open Access | Times Cited: 11
Jyotsna Gummadi, Xin Wei Wang, Changqing Xie
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 745-752
Open Access | Times Cited: 11
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma
Allison M. Kirk, Jeremy Chase Crawford, Ching‐Heng Chou, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101469-101469
Open Access | Times Cited: 4
Allison M. Kirk, Jeremy Chase Crawford, Ching‐Heng Chou, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101469-101469
Open Access | Times Cited: 4
Fibrolamellar hepatocellular carcinoma treated with chemotherapy and immunotherapy: a rare entity with unique characteristics
César Gutiérrez Pérez, María Pumares González, Noelia Espinosa Cabria, et al.
Revista Española de Enfermedades Digestivas (2025)
Open Access
César Gutiérrez Pérez, María Pumares González, Noelia Espinosa Cabria, et al.
Revista Española de Enfermedades Digestivas (2025)
Open Access
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Global Consensus from the PHITT Consortium Surrounding an Interim Chemotherapy Guidance for the Treatment of Children with Hepatoblastoma, Hepatocellular Neoplasm – Not Otherwise Specified (HCN-NOS), Hepatocellular Carcinoma and Fibrolamellar Carcinoma after Trial Closure
Irene Schmid, Allison F. O’Neill, Kenichiro Watanabe, et al.
EJC Paediatric Oncology (2025), pp. 100235-100235
Open Access
Irene Schmid, Allison F. O’Neill, Kenichiro Watanabe, et al.
EJC Paediatric Oncology (2025), pp. 100235-100235
Open Access
S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 02, pp. e213-e282
Open Access | Times Cited: 3
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 02, pp. e213-e282
Open Access | Times Cited: 3
DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma
K. Rosanna, Pei-Yin Tsai, Alaa R. Farghli, et al.
PLoS Genetics (2024) Vol. 20, Iss. 3, pp. e1011216-e1011216
Open Access | Times Cited: 3
K. Rosanna, Pei-Yin Tsai, Alaa R. Farghli, et al.
PLoS Genetics (2024) Vol. 20, Iss. 3, pp. e1011216-e1011216
Open Access | Times Cited: 3
DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma
Marina Chan, Songli Zhu, Manabu Nukaya, et al.
Gut (2025), pp. gutjnl-334274
Closed Access
Marina Chan, Songli Zhu, Manabu Nukaya, et al.
Gut (2025), pp. gutjnl-334274
Closed Access
Pathogenesis of primary liver carcinomas
Valérie Paradis, Jessica Zucman‐Rossi
Journal of Hepatology (2022) Vol. 78, Iss. 2, pp. 448-449
Open Access | Times Cited: 14
Valérie Paradis, Jessica Zucman‐Rossi
Journal of Hepatology (2022) Vol. 78, Iss. 2, pp. 448-449
Open Access | Times Cited: 14
An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer
Andres F. Espinoza, Pavan Kureti, Roma H. Patel, et al.
Hepatology Communications (2024) Vol. 8, Iss. 6
Open Access | Times Cited: 1
Andres F. Espinoza, Pavan Kureti, Roma H. Patel, et al.
Hepatology Communications (2024) Vol. 8, Iss. 6
Open Access | Times Cited: 1
Models of fibrolamellar carcinomas, tools for evaluation of a new era of treatments
Jinjia Song, Mengqi Lu, Zhiying He, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Jinjia Song, Mengqi Lu, Zhiying He, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma
Donald Long, Marina Chan, Mingqi Han, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101699-101699
Open Access | Times Cited: 1
Donald Long, Marina Chan, Mingqi Han, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101699-101699
Open Access | Times Cited: 1
Ruptured hepatocellular carcinoma developed in a normal liver in a young patient with a body mass index of 33 kg/m2
Naoki Kirihata, Yoshiko Nakano, Koki Moriyoshi, et al.
BMJ Case Reports (2024) Vol. 17, Iss. 12, pp. e262841-e262841
Closed Access | Times Cited: 1
Naoki Kirihata, Yoshiko Nakano, Koki Moriyoshi, et al.
BMJ Case Reports (2024) Vol. 17, Iss. 12, pp. e262841-e262841
Closed Access | Times Cited: 1
CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma
Manabu Nukaya, Crystal Cafferty, Katerina Zahed, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Manabu Nukaya, Crystal Cafferty, Katerina Zahed, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
